Polo‐like kinase 1 inhibitor NMS‐P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.

Autor: Gao, Jing, Huang, Weirong, Zhao, Senxia, Wang, Rong, Wang, Zhilin, Ye, Juanping, Lin, Lie, Cai, Weifeng, Mi, Yanjun

Publikováno v: Journal of Biochemical & Molecular Toxicology; Jan2024, Vol. 38 Issue 1, p1-11, 11p

Onvansertib inhibits the proliferation and improves the cisplatin-resistance of lung adenocarcinoma via β-catenin/c-Myc signaling pathway.

Autor: Wang R; Medical College, Guangxi University Nanning, Guangxi, P.R. China., Hou Y; Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Geng G; Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic Tumor Diagnosis and Treatment, Institute of Lung Cancer, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Zhu X; Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic Tumor Diagnosis and Treatment, Institute of Lung Cancer, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Wang Z; Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic Tumor Diagnosis and Treatment, Institute of Lung Cancer, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Cai W; Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic Tumor Diagnosis and Treatment, Institute of Lung Cancer, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Ye J; Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Zhao S; Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Mi Y; Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China., Jiang J; Department of Thoracic Surgery, Xiamen Key Laboratory of Thoracic Tumor Diagnosis and Treatment, Institute of Lung Cancer, The First Affiliated Hospital of Xiamen University, School of Clinical Medicine, Xiamen University Xiamen 361003, Fujian Province, P.R. China.

Publikováno v: American journal of cancer research [Am J Cancer Res] 2023 Feb 15; Vol. 13 (2), pp. 623-637. Date of Electronic Publication: 2023 Feb 15 (Print Publication: 2023).